Check for updates

OPEN ACCESS

EDITED BY Robert Wesolowski, Comprehensive Cancer Center, The Ohio State University, United States

REVIEWED BY

Amy Kerger, The Ohio State University, United States Jeffrey Hawley, Wexner Medical Center, The Ohio State University, United States

*CORRESPONDENCE Rong Wu Wurong7111@163.com

[†]These authors have contributed equally to this work and share first authorship

SPECIALTY SECTION

This article was submitted to Breast Cancer, a section of the journal Frontiers in Oncology

RECEIVED 23 January 2023 ACCEPTED 27 February 2023 PUBLISHED 16 March 2023

CITATION

Shao S, Yao M, Li C, Li X, Wang J, Chen J, Zheng Y and Wu R (2023) Ultrasound features for prediction of long-term outcomes of women with primary breast cancer <20 mm. *Front. Oncol.* 13:1103397. doi: 10.3389/fonc.2023.1103397

COPYRIGHT

© 2023 Shao, Yao, Li, Li, Wang, Chen, Zheng and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Ultrasound features for prediction of long-term outcomes of women with primary breast cancer <20 mm

Sihui Shao^{1†}, Minghua Yao^{1†}, Chunxiao Li¹, Xin Li¹, Jianfeng Wang², Jing Chen¹, Yi Zheng¹ and Rong Wu^{1*}

¹Department of Ultrasound, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, ²Department of General Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Background: Some women die despite the favorable prognosis of small breast cancers. Breast ultrasound features may reflect pathological and biological characteristics of a breast tumor. This study aimed to explore whether ultrasound features could identify small breast cancers with poor outcomes.

Methods: This retrospective study examined confirmed breast cancers with a size of <20 mm diagnosed in our hospital between 02/2008 and 08/2019. Clinicopathological and ultrasound features were compared between alive and deceased breast cancer patients. Survival was analyzed using the Kaplan-Meier curves. Multivariable Cox proportional hazards models were used to examine the factors associated with breast cancer-specific survival (BCSS) and disease-free survival (DFS).

Results: Among the 790 patients, the median follow-up was 3.5 years. The deceased group showed higher frequencies of spiculated (36.7% vs. 11.2%, P<0.001), anti-parallel orientation (43.3% vs. 15.4%, P<0.001), and spiculated morphology combined with anti-parallel orientation (30.0% vs. 2.4%, P<0.001). Among 27 patients with spiculated morphology and anti-parallel orientation, nine cancer-specific deaths and 11 recurrences occurred, for a 5-year BCSS of 77.8% and DFS of 66.7%, while 21 breast-cancer deaths and 41 recurrences occurred among the remaining patients with higher 5-year BCSS (97.8%, P<0.001) and DFS (95.4%, P<0.001). Spiculated and anti-parallel orientation (HR=7.45, 95%CI: 3.26-17.00; HR=6.42, 95%CI: 3.19-12.93), age \geq 55 years (HR=5.94, 95%CI: 2.24-15.72; HR=1.98, 95%CI: 1.11-3.54), and lymph nodes metastasis (HR=3.99, 95%CI: 1.89-8.43; HR=2.99, 95%CI: 1.71-5.23) were independently associated with poor BCSS and DFS.

Conclusions: Spiculated and anti-parallel orientation at ultrasound are associated with poor BCSS and DFS in patients with primary breast cancer <20 mm.

KEYWORDS

breast cancer, ultrasonography, mammary, early cancer, disease-free survival, cancer specific survival

Introduction

With the wide implementation of breast cancer imaging screening, an increasing number of small-sized breast cancers are being detected (1-3). Women with small breast cancer generally have favorable long-term outcomes (3-5). Nevertheless, breast cancer is a heterogeneous disease with complicated pathology and biological behavior, and some women eventually die of breast cancer or have early recurrence despite having a small tumor (6, 7). Indeed, tumor size by itself does not tell much about the biological behavior because a specific tumor size can result from an indolent disease that has been growing for some time or from a very aggressive disease that has been developing for a few weeks (5, 6, 8–10). In addition, even though tumor size is a well-recognized prognostic factor for invasive breast cancer, large ductal carcinoma *in situ* (DCIS) carries the risk of harboring microinvasive foci that can lead to poor outcomes (11).

Despite their value in predicting the long-term outcomes, traditional prognostic factors (such as pathological grade and lymph node status) and the more powerful molecular and genetic examinations might not be sufficient for the prognosis of small breast cancer (12–16). Some women with small breast cancer still die from breast cancer (6, 7). Clinicopathological factors like pathological tumor grade and lymph node status are commonly used for breast cancer sin larger ones (12–16). Thus, other reliable prognostic factors to identify the more aggressive subset among small breast cancers as early as possible are needed to ensure appropriate management.

Breast ultrasound features may reflect the underlying pathological manifestations and biological behavior of a breast tumor, which would be reliable imaging indicators for breast cancer outcomes (15, 19). Still, most studies focused on assessing the associations between ultrasound features and breast cancer risk categories like molecular type and histological grade (16–18). In contrast, studies examining the direct associations between ultrasound features and breast cancer mortality are insufficient, especially for small breast cancers <20 mm.

Therefore, this study aimed to explore whether ultrasound features could identify small breast cancers with poor outcomes.

Materials and methods

Study design and patients

This retrospective study included consecutive patients (including patients who came for the routine examination and patients with symptomatic complaints) with pathologically confirmed breast cancer with a size of <20 mm (histologic size) newly diagnosed in our hospital between February 2008 and August 2019. Only patients with a single lesion were included. Each patient underwent a preoperative whole breast ultrasound examination and received surgical therapy with negative margin.

The exclusion criteria were 1) with a history of breast cancer, 2) suspected or proven metastatic foci, 3) received any type of cancer

treatment before surgery, or 4) underwent biopsy without surgery. The minimum follow-up was 12 months.

This retrospective study was approved by the institutional ethics committee of Shanghai General Hospital. Written informed consent was waived by the institutional review board.

Ultrasound examination

All ultrasound examinations were performed in the routine clinical setting using an iU22 ultrasound system (Philips, Best, The Netherlands) with a 5-12-MHz linear transducer and an APlio 500 ultrasound system (Toshiba Corp., Tokyo, Japan) with a 10-MHz linear transducer. All ultrasound examinations were performed by radiologists with >3 years of experience in breast ultrasound screening.

Image analysis

For the present study, two radiologists with >3 years of experience in breast ultrasound imaging diagnosis reviewed the stored diagnostic images. The two radiologists were blind to other imaging examinations and the pathological results. The imaging features were analyzed using the BI-RADS lexicon, including shape (oval, round, or irregular), margin (circumscribed, indistinct, microlobulated, angular, or spiculated), orientation (≥ 1 or <1), presence of calcification or not, posterior features (no change, enhancement, focal acoustic shadow, combined pattern), echo pattern (hyperechoic, hypoechoic or mixed-echoic), and the grade of blood flow (absent, internal vascularity or vessels in the rim). If disagreement occurred, both readers re-assessed the ultrasound features classification and reached an agreement.

Pathology

All patients underwent surgery in the routine clinical management setting for such lesions as per the inclusion criteria. The results of the routine pathological examinations were defined as the final diagnosis. Tumor grade and lymph node status were assessed. Immunohistochemistry was performed to determine the expression of the estrogen receptor (ER), progesterone receptor (PR), human epidermal receptor 2 (HER2), and Ki67. The cut-off for positive ER and PR was 10% and 14% for positive Ki67. HER2 was defined as positive when 3+ or confirmed as positive using fluorescence *in situ* hybridization (20, 21).

Data collection and definitions

Patients' characteristics, pathological tumor characteristics, the primary surgical treatment (mastectomy or quadrantectomy and axillary procedures), and adjuvant therapy (chemotherapy or radiotherapy) were retrospectively collected from the patient charts. Breast cancer-specific survival (BCSS) was defined as the time from the first diagnosis to breast cancer-specific death. Disease-free survival (DFS) was considered the interval between the first diagnosis and the first evidence of recurrence, metastasis, or new diagnosis of breast carcinoma. For this study, the deaths were carefully reviewed and ruled by the investigators. Patients were divided into the deceased and alive groups based on whether they died of breast cancer or not.

Statistical analysis

Statistical analysis was performed using SPSS 19.0 (IBM Corp., Armonk, NY, USA). Two-sided P-values <0.05 were considered statistically significant. The ultrasound features of the malignant breast lesions and the clinicopathological characteristics between women with and without breast cancer death were compared using the chi-square test or Fisher's exact test, as appropriate. Continuous variables were analyzed using Student's t-test. The survival analyses were carried out using the Kaplan-Meier curves and the log-rank test. Multivariable Cox proportional hazards models were used to confirm the association of ultrasound features and outcomes after adjustment for other existing prognostic factors, including age, pathological grade, lymphovascular invasion, molecular biomarker, and adjuvant therapy. Covariables factors were further analyzed in lesions of 1-10 mm. Hazard ratios (HR) and 95% confidence intervals (CI) were used to describe the predictive factors.

Results

Characteristics of the patients

During the study period, 821 women were found with a breast mass <20 mm by histological measurement. Women with a history of breast cancer (n=21), with metastatic foci (n=2), who received treatment before surgery (n=5), or underwent biopsy without surgery (n=3) were excluded. Ultimately, 790 women with breast cancer <20 mm were included. The mean age at diagnosis was 56.3 ± 12.3 years, and the most common pathological type was invasive ductal carcinoma with an early stage, grade I and II, and negative lymph nodes status. The detailed clinicopathological characteristics are listed in Table 1.

Survival

The median follow-up for the 790 patients was 3.5 (interquartile range, 2.1-5.5) years, with a 96.2% BCSS and 93.4% DFS. Thirty patients died from breast cancer and four from other causes. When comparing the traditional risk factors between the two groups, age (P<0.001) and lymph nodes metastasis (P<0.001) were associated with breast cancer death. No significant differences were observed regarding the pathological type, histopathological grade, surgery type, adjuvant therapy, ER, PR, HER2, and Ki67, though negative

PR was with a borderline P-value (P=0.068) (Table 1). There were nine breast cancer deaths, and 11 recurrences occurred among patients with spiculated morphology and anti-parallel orientation, while 21 breast cancer deaths and 41 recurrences events among the remaining.

Association of ultrasound features with survival outcomes

As shown in Table 2, the shape, calcification, vascularity, posterior features, and echo patterns were not significantly different between the two groups (all P>0.05), while there were significant difference in the distribution of margin (P=0.006) and orientation (P<0.001) between the two groups. Compared with the survival group, the deceased group showed higher frequencies of spiculated (36.7% vs. 11.2%, P<0.001), anti-parallel orientation (43.3% vs. 15.4%, P<0.001), and spiculated morphology combined with anti-parallel orientation (30.0% vs. 2.4%, P<0.001) (Table 2 and Figure 1). The patients with spiculated morphology and antiparallel orientation had a lower 5-year BCSS (77.8% vs. 97.8%, P<0.001) and DFS (66.7% vs. 95.4%, P<0.001) (Figure 2) than the patients without those two features.

Multivariable analysis

Spiculated morphology and anti-parallel orientation (HR=7.45, 95%CI: 3.26-17.00, P<0.001), age \geq 55 years (HR=5.94, 95%CI: 2.24-15.72, P<0.001), and lymph nodes metastasis (HR=3.99, 95%CI: 1.89-8.43, P<0.001) were independently associated with poor BCSS (Table 3 and Figure 3). Spiculated morphologyand anti-parallel orientation (HR=6.42, 95%CI: 3.19-12.93, P<0.001), age \geq 55 years (HR=1.98, 95%CI: 1.11-3.54, P=0.021), and lymph nodes metastasis (HR=2.99, 95%CI: 1.71-5.23, P<0.001) were independently associated with poor DFS (Table 4).

When the risk factors were analyzed for tumors of 1-10 mm (n=158), the combination of spiculated morphology and antiparallel orientation was the only factor independently associated with BCSS (HR=12.69; 95%CI: 2.83-56.84, P=0.001). Among the 158 women with breast cancers of 1-10 mm, six had spiculated morphology combined with anti-parallel orientation and accounted for 43% (3/7) of the breast cancer deaths. Positive lymph node metastasis (n=184 patients) was also associated with BCSS when tumors >10 mm (HR=3.99; 95% CI, 1.89-8.43, P<0.001).

Discussion

This study aimed to explore whether ultrasound features could identify small breast cancers with poor outcomes. The results suggested that spiculated morphology and anti-parallel orientation at ultrasound were associated with poor BCSS and DFS in patients with breast cancer <20 mm.

The BCSS in the present study was 96.2%, which is consistent with previous studies in similar study populations (3–5). In the

TABLE 1 The association of histologic findings with survival outcomes.

Characteristics	Total (n=790)	Dead (n=30)	Alive (n=760)	Р
Age (years), mean ± SD	56.3 ± 12.3	68.1 ± 13.3	55.8 ± 12.1	< 0.001
Pathological type, n (%)				0.634
Intraductal carcinoma in situ	97 (12.3)	2 (6.7)	95 (12.5)	
Invasive ductal carcinoma	594 (75.2)	24 (80.0)	570 (75.0)	
Mucinous breast carcinoma	29 (3.7)	2 (6.7)	27 (3.6)	
Intraductal papillary carcinoma	30 (3.8)	0	30 (3.9)	
Invasive lobular carcinoma	25 (3.1)	1 (3.3)	24 (3.2)	
Others	15 (1.9)	1 (3.3)	14 (1.8)	
Grade, n (%)				0.514
Carcinoma in situ	75 (9.5)	1 (3.3)	74 (9.7)	
I	156 (19.7)	6 (20.0)	150 (19.7)	
П	363 (45.9)	13 (43.3)	350 (46.1)	
III	196 (24.8)	10 (33.3)	186 (24.5)	
Lymph nodes metastasis, n (%)				< 0.001
Negative	586 (74.2)	13 (43.3)	573 (75.4)	
Positive	204 (25.8)	17 (56.7)	187 (24.6)	
ER status, n (%)				0.981
Positive	570 (72.2)	21 (70.0)	549 (72.2)	
Negative	215 (27.2)	8 (26.7)	207 (27.2)	
Unknown	5 (0.6)	1 (3.3)	4 (0.5)	
PR status, n (%)				0.068
Positive	452 (57.2)	12 (40.0)	440 (57.9)	
Negative	330 (41.8)	17 (56.7)	313 (41.2)	
Unknown	8 (1.0)	1 (3.3)	7 (0.9)	
HER2 status, n (%)				0.828
Positive	146 (18.5)	6 (20.0)	140 (18.4)	
Negative	617 (78.1)	23 (76.7)	594 (78.2)	
Unknown	27 (3.4)	1 (3.3)	26 (3.4)	
Ki67, n (%)				
Positive	455 (57.6)	16 (53.3)	439 (57.8)	0.720
Negative	265 (33.5)	8 (26.7)	257 (33.8)	
Unknown	70 (8.9)	6 (20.0)	64 (8.4)	
Surgery type, n (%)				0.610
Mastectomy	457 (57.8)	16 (53.3)	441 (58.0)	
Quadrantectomy	333 (42.2)	14 (46.7)	319 (42.0)	
Surgery type of axillary, n (%)				0.484
Axillary dissection	571 (72.3)	20 (66.7)	551 (72.5)	
Axillary biopsy	219 (27.7)	10 (33.3)	209 (27.5)	

(Continued)

TABLE 1 Continued

Characteristics	Total (n=790)	Dead (n=30)	Alive (n=760)	Р
Adjuvant therapy, n (%)				0.086
Yes				
Chemotherapy	293 (37.1)	9 (30.0)	284 (37.4)	
Radiotherapy	117 (14.8)	3 (10.0)	114 (15.0)	
Chemotherapy and radiotherapy	52 (6.6)	1 (3.3)	51 (6.7)	
No	328 (41.5)	17 (56.7)	311 (40.9)	

TABLE 2 Association of ultrasound features with survival outcomes.

	Dead (n=30)	Alive (n=760)	Р
Shape			0.376
Regular	'		
Oval	0	38 (5.0)	
Round	3 (10.0)	47 (6.2)	
Irregular	27 (90.0)	675 (88.8)	
Margin			0.006
Circumscribed	6 (20.0)	159 (20.9)	0.903
Indistinct	5 (16.7)	235 (30.9)	0.096
Microlobulated	2 (6.7)	95 (12.5)	0.568
Angular	6 (20.0)	186 (24.5)	0.575
Spiculated	11 (36.7)	85 (11.2)	< 0.001
Orientation			<0.001
parallel	17 (56.7)	643 (84.6)	
not parallel	13 (43.3)	117 (15.4)	
Spiculated and anti-parallel orientation	9 (30.0)	18 (2.4)	< 0.001
Calcification			0.632
Presence	11 (36.7)	312 (41.1)	
Absence	19 (63.3)	448 (58.9)	
Vascularity			0.456
Absent	16 (53.3)	414 (54.5)	
Internal vascularity	14 (46.7)	302 (39.7)	
Vessels in rim	0	44 (5.8)	
Posterior features			0.229
No change	21 (70.0)	488 (64.2)	
Enhancement	3 (10.0)	105 (13.8)	
Focal acoustic shadow	3 (10.0)	138 (18.2)	
Combined pattern	3 (10.0)	29 (3.8)	

(Continued)

TABLE 2 Continued

	Dead (n=30)	Alive (n=760)	Р
Echo pattern			0.123
Hyperechoic	0	7 (0.9)	
Нуроесhoic	27 (90.0)	731 (96.2)	
Heterogenous	3 (10.0)	22 (2.9)	

present study, lymph node metastasis was a statistically significant predictor for small cancer. While no significant differences were observed regarding tumor grade. Among the 30 breast cancer deaths, only 10 patients were diagnosed as grade 3 tumors. Grade 3 tumors only accounted for 24.8% (196/790) among the small breast cancers including in this study, which is consistent with the theory that pathological grade tend to progress towards a higher grade during breast cancer growth (22). This biological characteristic might explain the different value of tumor grade in predicting outcome among breast cancers with different sizes. It was reported that the involvement of lymph nodes is strongly related to the metastatic potential of breast cancer (22), and lymph node involvement in early stage, small breast cancers might reflect a more aggressive biological behavior (5, 23). In this study, positive lymph node metastases were associated with poor BCSS in tumors of 10-20 mm, but not in tumors of 1-10 mm, as few positive lymph nodes were detected among tumors of 1-10 mm (n=20), which is supported by Tabar et al. (13). Hence, the traditional prognostic factors might not be reliable in breast cancers <20 mm.

Ultrasound imaging, which reflects the underlying pathological and biological characteristics of the breast tumors, might be a complementary and reliable way to characterize small breast cancers. Previous studies (13, 14) identified the role of mammography features in identifying high-risk small breast cancers. The association between ultrasound features and triplenegative breast cancer death was examined, but only 50.6% were tumor <20 mm (24). Chung et al. (25) found no association between ultrasound features and outcome by dividing tumors into mass or non-mass without detailed sonography features. Still, research concerning the predictive value of sonographic findings for longterm outcomes for small tumors is insufficient. In this study, spiculated morphologyand anti-parallel orientation, alone or in combination, were related to cancer death and recurrence, and the differences remained significant after adjusting for age, tumor grade, lymph node status, adjuvant therapy, and molecular biomarker. Survival to breast cancer <20 mm is favorable except for tumors with spiculated morphologycombined with a antiparallel orientation. It is proposed that a non-proportional growth is a suspicious indicator for malignancy and poor prognosis (19, 24, 26), which supports the results of the present study. Compared with ductal carcinoma in situ, invasive ductal carcinoma is more likely to have a non-proportional growth orientation (27). Guo et al. (19) assessed the value of ultrasound features in 336 breast cancers and supposed that vertical growth tends to correlate with high-risk breast cancer. At the pathological examination, indolent cancers generally show a homogeneous expansive growth, while a nonproportional growth at ultrasound reflects a heterogeneous infiltrating growth of malignant cells through lobule of mammary gland boundaries (24, 28, 29) and indicates a more aggressive biological behavior, particularly when it occurs early in breast cancer development.

In this study, the presence of spiculated morphology was another factor associated with poor prognosis. Results about the correlation between spiculated morphology and breast cancer prognosis remain conflicting. Wu et al. (30) proposed that spiculated margins are significantly related to positive HER2, a factor for high tumor grade and poor prognosis (31). While some studies consider spiculated morphology are more frequently associated with the low-grade tumor and positive ER and PR (21, 32). The conflicting results might be contributed to the analysis of breast cancers of different sizes. Besides, the long-term outcomes of small breast cancer were observed, and the association of spiculated morphology and cancer-related mortality was identified in this study, while most previous studies compared the imaging findings



FIGURE 1

Images in women with different long-term outcomes. (A), (A) A 54-year-old woman with breast cancer showing a parallel orientation, without spiculated morphology, and with no recurrence after 82 months of follow-up. (B) A 51-year-old woman with breast cancer with spiculated morphology and anti-parallel orientation. She died of distant metastasis 33 months from the first diagnosis. (C) A 50-year-old woman with breast cancer with spiculated morphology and anti-parallel orientation. She died of distant metastasis 33 months from the first diagnosis.



FIGURE 2

Breast cancer-specific survival and disease-free survival curves in women with small breast cancer. Spiculated morphology and anti-parallel orientation were strongly associated with a lower breast cancer-specific survival (A) and disease-free survival (B) compared with the remaining women with lesions of 1-20 mm. Subgroup A: Lesions with both spiculated morphology and anti-parallel orientation; Subgroup B: all other patients.

TABLE 3 Cox proportional	hazards models of the facto	ors for breast cancer death.
--------------------------	-----------------------------	------------------------------

Variables		HR	95% CI	Р
Age	≥55 vs. <55	5.94	2.24-15.72	< 0.001
Lymph nodes metastasis	Positive vs. negative	3.99	1.89-8.43	< 0.001
Sonography features	Subgroup A vs. B	7.45	3.26-17.00	< 0.001

Subgroup A, lesions with both spiculated morphology and anti-parallel orientation; Subgroup B, all other patients.

HR, hazard ratio; CI, confidence interval.

between different tumor attributes, including pathology characteristics and molecular biomarkers, which might explain the inconsistence. In terms of pathological manifestations, a spiculated margin is a reflection of the invasive growth of malignant cells into the normal surrounding tissues, indicating a high invasive capability (30, 33, 34). In addition, various growth factors (including the vascular endothelial growth factor and transforming growth factor) can be secreted by malignant cells to stimulate angiogenesis, infiltration, and metastasis (34, 35). An infiltrating growth early in tumor development might represent a more aggressive biological behavior and a graver prognosis, which was consistent to our results.

Casting-type calcification in mammography is a reliable predictor for a worse prognosis for small breast cancer (14), but no significant associations with BCSS and DFS were observed in the present study. It might be because of the sensitivity of ultrasound for calcifications. Molecular biomarkers are widely used in the clinical decision-making of breast cancer management, but no significant associations were observed between the biomarkers (ER, PR, HER2, and Ki67) and breast cancer outcomes in this study. Tryfonidis et al. (36) reported that small triple-negative and HER2-positive breast cancers tend to have a worse prognosis, while Galimberti et al. (37) and Bao et al. (7) proposed that there are no correlations between the status of ER, PR, HER2, and the outcome



FIGURE 3

Cox proportional hazards curve for death in women with spiculated morphology and anti-parallel orientation compared with the remaining women, according to the other five covariables factors. Spiculated morphology and anti-parallel orientation ultrasound features are associated with poor breast cancer-specific survival, and a difference was still observed after adjustment for other covariables. Subgroup A: Lesions with both spiculated morphology and anti-parallel orientation; Subgroup B: All other patients.

Variables		HR	95% Cl	Р
Age	≥55 vs. <55	1.98	1.11-3.54	0.021
Lymph nodes metastasis	Positive vs. negative	2.99	1.71-5.23	< 0.001
Sonography features	Subgroup A vs. B	6.42	3.19-12.93	< 0.001

TABLE 4 Cox proportional hazards models of the factors for disease-free survival.

Subgroup A, lesions with both spiculated morphology and anti-parallel orientation; Subgroup B, all other patients.

HR, hazard ratio; CI, confidence interval.

events. We are cautious about the results of the role of the molecular biomarker in breast cancer prognosis because of different cut-off values and a median follow-up time of only 3.5 years in this study, which might not be enough to observe the effects of molecular biomarkers on the outcomes of small breast cancer.

The treatment of each breast cancer is based on the careful consideration of recognized prognostic factors like tumor size, tumor grade, lymph node status, and molecular subtype. However, this decision-making assessment for small breast cancers might not be the same as for larger ones. Among the 30 breast cancer deaths in this study, 13 had negative lymph nodes, and 19 had grade 1-2 tumors, and one patient was even diagnosed with ductal carcinoma in situ at the final pathological examination. The combination of spiculated morphology and anti-parallel orientation was an independent predictor for breast cancer death in this study. Combining the imaging findings with the existing prognosis factors could contribute to the clinical decision-making by identifying the small breast cancers with a poor prognosis, for which more aggressive treatments might be warranted. Ultrasound is a readily available and inexpensive imaging modality that can be used alone or in combination with mammography. In a developing country where healthcare resources can be scarce in specific regions, standalone ultrasound can be used for breast cancer screening since some ultrasound systems are portable and mammography and magnetic resonance imaging might be unavailable.

There are some limitations to this study. First, it was a retrospective and single-center study, and bias might exist. Second, the classification of different ultrasound features is subjective and operator-dependent. Experienced radiologists are required to obtain reliable results. A high image resolution is required to observe the spiculated in small breast cancer. Third, the follow-up time was not long enough, and the number of breast cancer-specific death was small. Finally, as the number of deaths from cancer in the series is very low, there are very few findings that could be significant. Further studies are required.

Conclusion

The combined presence of spiculated morphology and antiparallel orientation in breast ultrasound might be associated with poor BCSS and DFS in patients with primary breast cancers <20 mm. Combining these imaging findings as complementary risk indicators with existing factors might improve the clinical evaluation in small breast cancers.

Data availability statement

The original contributions presented in the study are included in the article. Further inquiries can be directed to the corresponding author.

Ethics statement

This retrospective study was approved by the institutional ethics committee of Shanghai General Hospital. Written informed consent was waived by the institutional review board.

Author contributions

Conceptualization: RW; Data curation: SHS; Formal analysis: SHS; Funding acquisition: RW; Investigation: CXL; Methodology: YZ; Project administration: MHY; Resources: XL; Software: JC; Supervision: RW; Validation: JFW; Roles/writing - original draft: SHS; Writing - review and editing: MHY.

Funding

This work was supported by the National Natural Science Foundation of China (Grants No. 82071931, 82130057), program for Shanghai Outstanding Medical Academic Leaders (2019LJ18), the interdisciplinary program of Shanghai Jiaotong university (ZH2018ZDA17), the program from Science and Technology Commission of Shanghai Municipality (No. 20Y11912400), and the 2019 clinical research innovation team of Shanghai General Hospital(No. CTCCR-2019B05).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

References

1. Hanrahan EO, Gonzalez-Angulo AM, Giordano SH, Rouzier R, Broglio KR, Hortobagyi GN, et al. Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. *J Clin Oncol* (2007) 25:4952–60. doi: 10.1200/JCO.2006.08.0499

2. Melnikow J, Fenton JJ, Whitlock EP, Miglioretti DL, Weyrich MS, Thompson JH, et al. Supplemental screening for breast cancer in women with dense breasts: a systematic review for the U.S. preventive services task force. *Ann Intern Med* (2016) 164:268–78. doi: 10.7326/M15-1789

3. Welch HG, Prorok PC, O'Malley AJ, Kramer BS. Breast-cancer tumor size, overdiagnosis, and mammography screening effectiveness. N Engl J Med (2016) 375:1438-47. doi: 10.1056/NEJMoa1600249

4. Sopik V, Narod SA. The relationship between tumour size, nodal status and distant metastases: on the origins of breast cancer. *Breast Cancer Res Treat* (2018) 170:647–56. doi: 10.1007/s10549-018-4796-9

5. Wo JY, Chen K, Neville BA, Lin NU, Punglia RS. Effect of very small tumor size on cancer-specific mortality in node-positive breast cancer. *J Clin Oncol* (2011) 29:2619–27. doi: 10.1200/JCO.2010.29.5907

6. Comen EA, Norton L, Massague J. Breast cancer tumor size, nodal status, and prognosis: biology trumps anatomy. *J Clin Oncol* (2011) 29:2610–2. doi: 10.1200/ JCO.2011.36.1873

 Bao J, Donovan C, Amersi F, Zhang X, Giuliano AE, Chung A. Outcomes in patients with small node-negative invasive breast cancer. *Breast J* (2019) 25:638–43. doi: 10.1111/tbj.13288

8. Provencher L, Diorio C, Hogue JC, Doyle C, Jacob S. Does breast cancer tumor size really matter that much? *Breast* (2012) 21:682–5. doi: 10.1016/j.breast.2012.07.003

9. Foulkes WD, Reis-Filho JS, Narod SA. Tumor size and survival in breast cancer-a reappraisal. *Nat Rev Clin Oncol* (2010) 7:348-53. doi: 10.1038/nrclinonc.2010.39

10. Narod SA. Age of diagnosis, tumor size, and survival after breast cancer: implications for mammographic screening. *Breast Cancer Res Treat* (2011) 128:259–66. doi: 10.1007/s10549-010-1318-9

11. Giannakeas V, Sopik V, Narod SA. Association of a diagnosis of ductal carcinoma *in situ* with death from breast cancer. *JAMA Netw Open* (2020) 3: e2017124. doi: 10.1001/jamanetworkopen.2020.17124

12. Januskeviciene I, Petrikaite V. Heterogeneity of breast cancer: the importance of interaction between different tumor cell populations. *Life Sci* (2019) 239:117009. doi: 10.1016/j.lfs.2019.117009

13. Tabar L, Tony Chen HH, Amy Yen MF, Tot T, Tung TH, Chen LS, et al. Mammographic tumor features can predict long-term outcomes reliably in women with 1-14-mm invasive breast carcinoma. *Cancer* (2004) 101:1745–59. doi: 10.1002/cncr.20582

14. Tabár L, Chen HH, Duffy SW, Yen MF, Chiang CF, Dean PB, et al. A novel method for prediction of long-term outcome of women with T1a, T1b, and 10-14 mm invasive breast cancers: a prospective study. *Lancet* (2000) 355:429–33. doi: 10.1016/S0140-6736(00)82008-5

15. Wu WY, Tabar L, Tot T, Fann CY, Yen AM, Chen SL, et al. Imaging biomarkers as predictors for breast cancer death. *J Oncol* (2019) 2019:2087983. doi: 10.1155/2019/2087983

16. Tot T. The limited prognostic value of measuring and grading small invasive breast carcinomas: the whole sick lobe versus the details within it. *Med Sci Monit* (2006) 12:Ra170–5.

17. Waks AG, Winer EP. Breast cancer treatment: a review. *JAMA* (2019) 321:288–300. doi: 10.1001/jama.2018.19323

18. Harbeck N, Gnant M. Breast cancer. Lancet (2017) 389:1134-50. doi: 10.1016/ S0140-6736(16)31891-8

19. Guo Q, Zhang L, Di Z, Ning C, Dong Z, Li Z, et al. Assessing risk category of breast cancer by ultrasound imaging characteristics. *Ultrasound Med Biol* (2018) 44:815–24. doi: 10.1016/j.ultrasmedbio.2017.12.001

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

20. Wan CF, Du J, Fang H, Li FH, Zhu JS, Liu Q. Enhancement patterns and parameters of breast cancers at contrast-enhanced US: correlation with prognostic factors. *Radiology* (2012) 262:450–9. doi: 10.1148/radiol.11110789

21. Wen X, Yu Y, Yu X, Cheng W, Wang Z, Liu L, et al. Correlations between ultrasonographic findings of invasive lobular carcinoma of the breast and intrinsic subtypes. *Ultraschall Med* (2019) 40:764–70. doi: 10.1055/a-0715-1668

22. Tubiana M, Koscielny S. The rationale for early diagnosis of cancer-the example of breast cancer. *Acta Oncol* (1999) 38:295–303. doi: 10.1080/028418699431357

23. Husemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E, et al. Systemic spread is an early step in breast cancer. *Cancer Cell* (2008) 13:58–68. doi: 10.1016/j.ccr.2007.12.003

24. Wang H, Zhan W, Chen W, Li Y, Chen X, Shen K. Sonography with vertical orientation feature predicts worse disease outcome in triple negative breast cancer. *Breast* (2020) 49:33–40. doi: 10.1016/j.breast.2019.10.006

25. Chung SR, Choi WJ, Cha JH, Kim HH, Shin HJ, Chae EY, et al. Prognostic factors predicting recurrence in invasive breast cancer: An analysis of radiological and clinicopathological factors. *Asian J Surg* (2019) 42:613–20. doi: 10.1016/j.asjsur.2018.10.009

26. Cao XL, Bao W, Zhu SG, Wang LH, Sun MH, Wang L, et al. Contrast-enhanced ultrasound characteristics of breast cancer: correlation with prognostic factors. *Ultrasound Med Biol* (2014) 40:11–7. doi: 10.1016/j.ultrasmedbio.2013.08.014

27. Kim SH, Seo BK, Lee J, Kim SJ, Cho KR, Lee KY, et al. Correlation of ultrasound findings with histology, tumor grade, and biological markers in breast cancer. *Acta Oncol* (2008) 47:1531–8. doi: 10.1080/02841860801971413

28. Paulinelli RR, Freitas-Junior R, de Lucena C, Moreira MA, de Moraes VA, Bernardes-Júnior JR, et al. Sonobreast: predicting individualized probabilities of malignancy in solid breast masses with echographic expression. *Breast J* (2011) 17:152–9. doi: 10.1111/j.1524-4741.2010.01046.x

29. Hong AS, Rosen EL, Soo MS, Baker JA. BI-RADS for sonography: positive and negative predictive values of sonographic features. *AJR Am J Roentgenol* (2005) 184:1260–5. doi: 10.2214/ajr.184.4.01841260

30. Wu T, Li J, Wang D, Leng X, Zhang L, Li Z, et al. Identification of a correlation between the sonographic appearance and molecular subtype of invasive breast cancer: A review of 311 cases. *Clin Imaging* (2019) 53:179–85. doi: 10.1016/j.clinimag.2018.10.020

31. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. *Science* (1987) 235:177–82. doi: 10.1126/science.3798106

32. Au FW, Ghai S, Lu FI, Moshonov H, Crystal P. Histological grade and immunohistochemical biomarkers of breast cancer: correlation to ultrasound features. J Ultrasound Med (2017) 36:1883–94. doi: 10.1002/jum.14247

33. Yu X, Hao X, Wan J, Wang Y, Yu L, Liu B. Correlation between ultrasound appearance of small breast cancer and axillary lymph node metastasis. *Ultrasound Med Biol* (2018) 44:342–9. doi: 10.1016/j.ultrasmedbio.2017.09.020

34. Walker RA. The complexities of breast cancer desmoplasia. Breast Cancer Res (2001) 3:143-5. doi: 10.1186/bcr287

35. Colpaert C, Vermeulen P, van Beest P, Goovaerts G, Weyler J, Van Dam P, et al. Intratumoral hypoxia resulting in the presence of a fibrotic focus is an independent predictor of early distant relapse in lymph node-negative breast cancer patients. *Histopathology* (2001) 39:416–25. doi: 10.1046/j.1365-2559.2001.01238.x

36. Tryfonidis K, Zardavas D, Cardoso F. Small breast cancers: when and how to treat. *Cancer Treat Rev* (2014) 40:1129–36. doi: 10.1016/j.ctrv.2014.09.004

37. Galimberti V, Cole BF, Viale G, Veronesi P, Vicini E, Intra M, et al. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. *Lancet Oncol* (2018) 19:1385–93. doi: 10.1016/S1470-2045(18)30380-2